A Prospective Study Of The Serum Prostate Specific Antigen Concentrations And Gleason Histologic Scores Of Black And White Men With Prostate Carcinoma

Jackson E. Fowler, Jr., Steven A. Bigler
Abramson Cancer Center of the University of Pennsylvania
Last Modified: November 1, 2001

Share article


Reviewers: Li Liu, MD
Source: Cancer, 86(5):836-841, September 1999

Background

Successful stratification of patients for any risk variable would enhance our understanding of the disease and therefore enable us to develop effective strategies for managing subsets of patients. This is especially true for prostate cancer since African American men have the highest incidence of prostate carcinoma in the world. Drs. Fowler and Bigler reported this interesting study to confirm and expand our knowledge of racial differences in prostate carcinoma.

Methods

Fowler and Bigler prospectively studied 796 consecutive men (465 black and 331 white) with prostate cancer at the VA Hospital associated with the University of Mississippi.

Results

  • High mean serum PSA concentrations and Gleason score 8-10 tumors were much more common among blacks with prostate cancer than whites regardless of the volume of the prostate or age of the patient.
  • For patients 65 years or younger, the mean PSA values of black and white men with localized cancer were 11.6 and 6.9, respectively (p=0.0009).

Discussion

It has been hypothesized that black Americans have higher circulating levels of testosterone than whites. This may be one explanation for racial differences in the risk of developing prostate cancer. The implication is that black American men should be tested for prostate carcinoma at an earlier age than white men. More studies are needed to explore the underlying genetic differences, which are linked, to the risk of prostate carcinoma.



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More